---
title: "Semaglutide SWOT Analysis - Diabetes"
date: 2025-11-27
drug: semaglutide
indication: diabetes
analyst: drug-swot-analysis
data_sources:
  - clinical_trials: 424 trials
  - fda_labels: 3 labels
  - publications: 191 papers
  - patents: 86 patents (45 families)
swot_summary:
  strengths: 3
  weaknesses: 0
  opportunities: 2
  threats: 1
overall_position: Strong - Leverage strengths to capitalize on opportunities
---

# Drug SWOT Analysis: semaglutide

**Indication:** diabetes
**Analysis Date:** 2025-11-27
**Generated by:** Pharmaceutical Research Intelligence Platform

---

## Executive Summary

This SWOT analysis synthesizes data from multiple authoritative sources to provide a strategic assessment of **semaglutide** for **diabetes**.

### Data Sources Summary

| Source | Count | Details |
|--------|-------|---------|
| Clinical Trials | 424 | Phase distribution: {'Phase3': 105, 'Phase4': 67, 'Phase1': 77, 'Na': 33, 'Unknown': 76, 'Phase2': 48, 'Phase2, Phase3': 11, 'Early Phase1': 3, 'Phase1, Phase2': 4}. Status: 161 recruiting, 223 completed |
| FDA Labels | 3 | Found 3 FDA-registered brand name(s) for semaglutide |
| Publications | 191 | Found 191 recent publications. Distribution: {'2025': 189, '2024': 1} |
| Patents | 86 | Found 86 patents from 32 assignees. Publication years: 2018-2025. Estimated expiry: 2038-2045 |

---

## SWOT Analysis

### üí™ Strengths


**1. Regulatory: FDA-approved with published drug label**
- Evidence: 3 FDA label(s) available

**2. Scientific Evidence: Robust scientific evidence with 191 recent publications**
- Evidence: Publication distribution: {'2025': 189, '2024': 1}

**3. Intellectual Property: Patent portfolio with 86 patents across 45 patent families**
- Evidence: Top assignees: NOVO NORDISK AS, ENZYPEP B V, MAPI PHARMA LTD

### ‚ö†Ô∏è Weaknesses

*No significant weaknesses identified from available data.*

### üöÄ Opportunities

**1. Pipeline Expansion: 161 actively recruiting trials indicate pipeline growth**
- Evidence: Trial status: {'Completed': 223, 'Not Yet Recruiting': 41, 'Recruiting': 81, 'Unknown': 22, 'Active Not Recruiting': 39, 'Terminated': 5, 'Enrolling By Invitation': 6, 'Suspended': 3, 'Withdrawn': 4}

**2. Scientific Interest: Strong recent research momentum with 190 publications in 2024-2025**
- Evidence: Year distribution: {'2025': 189, '2024': 1}

### üî¥ Threats

**1. Competition: Highly competitive therapeutic area with 424 trials**
- Evidence: Large number of trials suggests crowded market


---

## Methodology

This analysis was generated using the Pharmaceutical Research Intelligence Platform's multi-source data collection approach:

1. **Clinical Trials**: Searched ClinicalTrials.gov for all trials mentioning "semaglutide" and "diabetes"
2. **FDA Data**: Retrieved official drug labels and safety information from FDA databases
3. **Publications**: Analyzed recent scientific literature (2022-2025) from PubMed
4. **Patents**: Searched Google Patents Public Datasets for intellectual property landscape, including patent families, expiry estimates, and assignee analysis

### Data Quality Notes

- Analysis based on publicly available data as of 2025-11-27
- SWOT categorization uses objective criteria from collected data
- Some data sources may be incomplete or pending updates

---

## Strategic Recommendations

Based on this SWOT analysis, key strategic considerations include:

- **Overall Position**: Strong - Leverage strengths to capitalize on opportunities
- **Priority**: Accelerate development and market expansion initiatives

---

*This report was automatically generated. For detailed data, please refer to source databases.*
